NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MBF Therapeutics

MBF Therapeutics

Private
Warminster, EnglandHealthcare & Life Scienceshttps://mbftherapeutics.com/

Last Round

Angel

Oct 12, 2022

Total Funding Raised

$3.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

MBF Therapeutics is a biotechnology company that develops a DNA vaccine platform designed to create products for infectious diseases and cancer in the animal health markets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

animal immunotherapiesDNA vaccine platformanimal pharmaT-cell immunotherapyveterinary oncologyanimal vaccineslivestock vaccinesAfrican Swine Fever vaccinecanine cancer treatmentcell-mediated immunitynanoparticle delivery systemcompanion animal healthclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MBF Therapeutics Comparables

Compare MBF Therapeutics with similar companies based on industry and business-model similarity.

MBF Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Torigen Pharmaceuticals, Inc.
76%
Vetigenics Inc.
74%
Mazen Animal Health
74%

MBF Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AngelOct 12, 2022
VC RoundMay 16, 2018
SeedJan 31, 2017

Key People

Founding team and executive leadership

Thomas Tillett

CEO & President, CEO & President MBF Therapeutics

Executive Team

MBF Therapeutics Investors

Notable investors and investment history

MBF Therapeutics investors
InvestorRounds
Benjamin Franklin Technology PartnersVC Round, Angel, Seed
Keiretsu Forum Mid-AtlanticSeries S-2

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 11, 2026

    Monthly visitors grew 99% MoM, reaching 2.4K.

  • Feb 25, 2025

    Monthly visitors grew 60% MoM.

MBF Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MBF Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MBF Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWarminster, England
Employee Range7
Year Founded2008
Last FundingOct 12, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.